Caption Management’s IGM Biosciences IGMS Stock Holding History

Caption Management’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,668	Closed	-$307K	–	1743
2021 Q3	$307K	Buy	+4,668	New	+$357K	﹤0.01%	1290

Other funds holding IGMS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caption Management's IGMS Position: Q4 2021 in Review

Caption Management sold out of IGM Biosciences (IGMS) in Q4 2021, closing a stake of 4,668 shares — an estimated $307K sold.

Caption Management first reported a position in IGMS in Q3 2021 and held it in 1 quarter. The position peaked at $307K in Q3 2021. 87 funds tracked by Wall St. Rank hold IGMS as of Q4 2021.

Caption Management reported no remaining IGM Biosciences position as of Q4 2021 after selling out during the quarter.
Caption Management sold 4,668 IGM Biosciences shares in Q4 2021, an estimated $307K.
Caption Management first reported a position in IGM Biosciences in Q3 2021 and held it in 1 quarter.
Caption Management's IGM Biosciences position peaked at $307K in Q3 2021.
87 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2021.

Based on Caption Management's 13F filing for Q4 2021, filed 11 Feb 2022.